mammalian cell lines l428 (DSMZ)
Structured Review

Mammalian Cell Lines L428, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 85 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mammalian cell lines l428/product/DSMZ
Average 94 stars, based on 85 article reviews
Images
1) Product Images from "Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors"
Article Title: Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors
Journal: bioRxiv
doi: 10.1101/2025.01.24.631210
Figure Legend Snippet: a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days under low serum conditions; mean ± s.d. is depicted (n = 3); P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. b , waterfall plots (ordered by increasing CRISPR gene effect score) showing genetic dependencies of 3 cHL cell lines (L1236, UHO1, L428). c, d . scatterplot of IL4R and IL13RA1 (c) and IL4R and STAT6 (d) gene effect scores across the DepMap dataset. e , effect of CRISPR/Cas9-mediated knock out of IL13RA1 or IL4R on L1236 cell viability (viable cell counts). f , rainplot of IL13 expression showing that the cHL cell lines (L1236, L428, and UHO1) show outlier expression of IL13. g , effect of CRISPR/Cas9-mediated knock out of IL13 on L1236 cell viability (viable cell counts), with or without recombinant IL13 supplementation (rIL13). h , dose-response analysis of tralokinumab, lebrikizumab, and dupilumab on L1236 cells. IC 50 values (95% confidence interval) are indicated on the right (n = 2); mean ± s.d. is depicted. The relative viability values represent the mean of two independent experimental replicates. i , time course analysis of the effect of tralokinumab, lebrikizumab, dupilumab (0.5 µM each), and isotype control antibody on L1236 cell viability (n = 3); mean ± s.d. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. j , schematic representation of the proposed model of spatial organization and interactions that mediate tumor cell growth within the intact cHL tumor microenvironment. The data in e, g, and i are representative of three independent experiments.
Techniques Used: Recombinant, Control, Comparison, CRISPR, Knock-Out, Expressing, Clinical Proteomics

